Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease

Gene Therapy

Volumn 13, Issue 23, 2006, Pages 1665-1676

  Muhle C ^a,b   Neuner, A ^a   Park, J ^a,b   Pacho, F ^b   Jiang, Q ^a   Waddington, S N ^c   Schneider, H ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; KALININ; LAMININ; LAMININ BETA3; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ADENOVIRUS VECTOR; AMNION FLUID; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BETA CHAIN; COITUS; EPIDERMIS; EPIDERMOLYSIS BULLOSA; GASTROINTESTINAL MUCOSA; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENODERMATOSIS; HETEROZYGOTE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LIFESPAN; MAXIMUM PERMISSIBLE DOSE; MOTHER; MOUSE; NEWBORN; NONHUMAN; PARVOVIRUS VECTOR; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REPORTER GENE; RESPIRATORY TRACT MUCOSA; TRANSGENE;

ADENOVIRIDAE; AMNION; ANIMALS; ANIMALS, NEWBORN; BASEMENT MEMBRANE; CELL ADHESION MOLECULES; DEPENDOVIRUS; EPIDERMOLYSIS BULLOSA, JUNCTIONAL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; INJECTIONS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PREGNANCY; SKIN; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS - 2; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MURINAE;

EID: 33751173879     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302832     Document Type: Article

References (49)

1. Eady RA. Epidermolysis bullosa: Scientific advances and therapeutic challenges. J Dermatol 2001; 28: 638-640.
2. Roseeuw D, De Raeve L, Dangoisse C, Ramet J. Treatment of epidermolysis bullosa with human cultured epidermal allografts. Dermatology 1994; 189 (Suppl 2): 68-70.
3. Jiang QJ, Izakovic J, Zenker M, Fartasch M, Meneguzzi G, Rascher W et al. Treatment of two patients with Herlitz junctional epidermolysis bullosa with artificial skin bioequivalents. J Pediatr 2002; 141: 553-559.
4. Kopp J, Horch RE, Stachel KD, Holter W, Kandler MA, Hertzberg H et al. Hematopoietic stem cell transplantation and subsequent 80% skin exchange by grafts from the same donor in a patient with Herlitz disease. Transplantation 2005; 79: 255-256.
5. Schneider H, Muhle C, Douar AM, Waddington S, Jiang QJ, von der Mark K et al. Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administered in utero. J Gene Med 2002; 4: 46-53.
6. Waddington SN, Buckley SM, Nivsarkar M, Jezzard S, Schneider H, Dahse T et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood 2003; 101: 1359-1366.
7. Waddington SN, Nivsarkar MS, Mistry AR, Buckley SM, Kemball-Cook G, Mosley KL et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 2004; 104: 2714-2721.
8. Schneider H, Coutelle C. In utero gene therapy: The case for. Nat Med 1999; 5: 256-257.
9. Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science 1999; 285: 2084-2088.
10. Porada CD, Tran N, Eglitis M, Moen RC, Troutman L, Flake AW et al. In utero gene therapy: Transfer and long-term expression of the bacterial neo(r) gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther 1998; 9: 1571-1585.
11. Schneider H, Adebakin S, Themis M, Cook T, Douar AM, Pavirani A et al. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: A model for the prenatal treatment of haemophilia B. J Gene Med 1999; 1: 424-432.
12. Lipshutz GS, Gruber CA, Cao Y, Hardy J, Contag CH, Gaensler KM. In utero delivery of adeno-associated viral vectors: Intraperitoneal gene transfer produces long-term expression. Mol Ther 2001; 3: 284-292.
13. Mitchell M, Jerebtsova M, Batshaw ML, Newman K, Ye X. Longterm gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Therapy 2000; 7: 1986-1992.
14. Boyle MP, Enke RA, Adams RJ, Guggino WB, Zeitlin PL. In utero AAV-mediated gene transfer to rabbit pulmonary epithelium. Mol Ther 2001; 4: 115-121.
15. Seppen J, van der Rijt R, Looije N, van Til NP, Lamers WH, Oude Elferink RP. Long-term correction of bilirubin UDPglucuronyl-transferase deficiency in rats by in utero lentiviral gene transfer. Mol Ther 2003; 8: 593-599.
16. Dejneka NS, Surace EM, Aleman TS, Cideciyan AV, Lyubarsky A, Savchenko A et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 2004; 9: 182-188.
17. Themis M, Schneider H, Kiserud T, Cook T, Adebakin S, Jezzard S et al. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Therapy 1999; 6: 1239-1248.
18. David A, Cook T, Waddington S, Peebles D, Nivsarkar M, Knapton H et al. Ultrasound-guided percutaneous delivery of adenoviral vectors encoding the beta-galactosidase and human factor IX genes to early gestation fetal sheep in utero. Hum Gene Ther 2003; 14: 353-364.
19. Masunaga T, Shimizu H, Ishiko A, Tomita Y, Aberdam D, Ortonne JP et al. Localization of laminin-5 in the epidermal basement membrane. J Histochem Cytochem 1996; 44: 1223-1230.
20. McMillan JR, McGrath JA, Tidman MJ, Eady RA. Hemidesmosomes show abnormal association with the keratin filament network in junctional forms of epidermolysis bullosa. J Invest Dermatol 1998; 110: 132-137.
21. Utani A, Nomizu M, Timpl R, Roller PP, Yamada Y. Laminin chain assembly. Specific sequences at the C terminus of the long arm are required for the formation of specific double- and triple-stranded coiled-coil structures. J Biol Chem 1994; 269: 19167-19175.
22. Peters BP, Hartle RJ, Krzesicki RF, Kroll TG, Perini F, Balun JE et al. The biosynthesis, processing, and secretion of laminin by human choriocarcinoma cells. J Biol Chem 1985; 260: 14732-14742.
23. Pulkkinen L, Uitto J. Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol 1999; 18: 29-42.
24. Muhle C, Jiang QJ, Charlesworth A, Bruckner-Tuderman L, Meneguzzi G, Schneider H. Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: Molecular basis and clinical course of Herlitz disease. Hum Genet 2005; 116: 33-42.
25. Walther W, Stein U. Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs 2000; 60: 249-271.
26. Monahan PE, Samulski RJ. AAV vectors: Is clinical success on the horizon? Gene Therapy 2000; 7: 24-30.
27. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
28. Kuroki T, Kashiwagi M, Ishino K, Huh N, Ohba M. Adenovirus-mediated gene transfer to keratinocytes - a review. J Investig Dermatol Symp Proc 1999; 4: 153-157.
29. Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Therapy 1999; 6: 432-441.
30. Buning H, Braun-Falco M, Hallek M. Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs 2004; 177: 139-150.
31. Kuster JE, Guarnieri MH, Ault JG, Flaherty L, Swiatek PJ. IAP insertion in the murine LamB3 gene results in junctional epidermolysis bullosa. Mamm Genome 1997; 8: 673-681.
32. Ryan MC, Lee K, Miyashita Y, Carter WG. Targeted disruption of the LAMA3 gene in mice reveals abnormalities in survival and late stage differentiation of epithelial cells. J Cell Biol 1999; 145: 1309-1323.
33. Boyle MP, Enke RA, Mogayzel Jr PJ, Guggino WB, Martin DB, Agarwal S et al. Effect of adeno-associated virus-specific immunoglobulin G in human amniotic fluid on gene transfer. Hum Gene Ther 2003; 14: 365-373.
34. Douar AM, Themis M, Sandig V, Friedmann T, Coutelle C. Effect of amniotic fluid on cationic lipid mediated transfection and retroviral infection. Gene Therapy 1996; 3: 789-796.
35. Gagnoux-Palacios L, Hervouet C, Spirito F, Roques S, Mezzina M, Danos O et al. Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. J Gene Med 2005; 7: 1178-1186.
36. Braun-Falco M, Eisenried A, Buning H, Ring J. Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase. Arch Dermatol Res 2005; 296: 528-535.
37. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
38. Chen Y, Luk KD, Cheung KM, Lu WW, An XM, Ng SS et al. Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem Biophys Res Commun 2004; 317: 675-681.
39. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet 2003; 40: 721-728.
40. Meng X, Klement JF, Leperi DA, Birk DE, Sasaki T, Timpl R et al. Targeted inactivation of murine laminin gamma2-chain gene recapitulates human junctional epidermolysis bullosa. J Invest Dermatol 2003; 121: 720-731.
41. Arin MJ, Roop DR. Inducible mouse models for inherited skin diseases: implications for skin gene therapy. Cells Tissues Organs 2004; 177: 160-168.
42. Gache Y, Baldeschi C, Del Rio M, Gagnoux-Palacios L, Larcher F, Lacour JP, Meneguzzi G. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 2004; 15: 921-933.
43. Jiang QJ, Uitto J. Animal models of epidermolysis bullosa - targets for gene therapy. J Invest Dermatol 2005; 124: Xi-xiii.
44. Spirito F, Capt A, Rio MD, Larcher F, Guaguere E, Danos O et al. Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: Establishment of an immunocompetent animal model for cutaneous gene therapy. Biochem Biophys Res Commun 2006; 339: 769-778.
45. Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 2004; 10: 660-670.
46. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
47. Samulski RJ, Sally M, Muzyczka N. Adeno-associated viral vectors. In: Friedman T (ed). The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1999, pp 131-172.
48. Marinkovich MP, Lunstrum GP, Burgeson RE. The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor. J Biol Chem 1992; 267: 17900-17906.
49. Jakob M, Muhle C, Park J, Weiss S, Waddington S, Schneider H. No evidence for germ-line transmission following prenatal and early postnatal AAV-mediated gene delivery. J Gene Med 2005; 7: 630-637.